PITTSFIELD, Mass.--(BUSINESS WIRE)--At the 50th meeting of the American Society for Clinical Oncology (ASCO), Nuclea Biotechnologies presented the conclusion of a recent study which reinforced the findings of previous clinical studies pointing to the prognostic and predictive value of serum HER-2/neu testing for patients with metastatic breast cancer (MBC).
Help employers find you! Check out all the jobs and post your resume.
